CRO企业研发外包道德风险评估与控制研究

发布时间：2018-03-04 03:22

本文选题：合同研究组织　切入点：制药企业　出处：《中国新药杂志》2015年17期 　论文类型：期刊论文

【摘要】：制药企业与医药研发外包企业之间存在信息不对称,容易出现医药研发外包企业的道德风险问题。本研究运用风险矩阵法对合同研究组织(CRO)企业的道德风险进行评估,发现研发努力程度、信息泄露和隐藏风险对研发外包项目的影响程度都很高。本文针对研发外包企业可能发生的道德风险,建议在研发第一阶段采用固定支付和收益共享合同激励CRO企业,并提出了在研发第2阶段根据道德风险发生的概率,调整收益共享系数和决定是否配置控制权,从而降低CRO企业的信息泄露和隐藏风险的对策。
[Abstract]:There is information asymmetry between pharmaceutical enterprises and pharmaceutical R & D outsourcing enterprises, which is prone to the moral hazard of pharmaceutical R & D outsourcing enterprises. In this study, the risk matrix method is used to evaluate the moral hazard of CRO (a contract research organization). It is found that the degree of R & D efforts, information leakage and hidden risks have a high impact on R & D outsourcing projects. In the first stage of R & D, it is suggested that CRO enterprises should be encouraged by fixed payment and revenue-sharing contracts. In the second stage of R & D, the income sharing coefficient should be adjusted according to the probability of moral hazard and the decision on whether to allocate control power should be made. In order to reduce the CRO enterprise information leakage and hidden risk countermeasures.
【作者单位】：安徽中医药大学医药经济管理学院;
【基金】：安徽省高校人文社科研究重点项目(SK2014A292)
【分类号】：F426.72;R95

【相似文献】